David J. Wambeke - 01 Jun 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: Chief Business Officer
Signature: /s/ Scott Kellen, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 01 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2025, 16:19:13 UTC
Previous filing: 03 Jun 2024
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wambeke David J.	Chief Business Officer	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS	/s/ Scott Kellen, attorney-in-fact	03 Jun 2025	0001971798

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						527,114	01 Jun 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+250,000		$0.000000	250,000	01 Jun 2025	Common Shares	250,000	$4.11	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026.